Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2012-004956-12-IT
EUCTR2012-004956-12-IT
Active, Not Recruiting
Phase 1

A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and correlative science studies attempting to identify predictors of response - Neoadjuvant eribulin

ISTITUTO NAZIONALE PER LA CURA TUMORI0 sites48 target enrollmentJanuary 11, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsHALAVEN*EV 6FL 2ML 0,44MG/ML

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
ISTITUTO NAZIONALE PER LA CURA TUMORI
Enrollment
48
Status
Active, Not Recruiting
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 11, 2013
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
ISTITUTO NAZIONALE PER LA CURA TUMORI

Eligibility Criteria

Inclusion Criteria

  • •tumor \>\= 2 cm
  • •HER2 negative
  • •ER PgR negative
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 48
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 48

Exclusion Criteria

  • •prior treatment for breast cancer
  • •metastatic cancer
  • •bilateral invasive breast cancer
  • •multicentric breast cancer
  • •pre\-existing peripheral neuropathy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
An open label, single-arm, phase 2 study od neoadjuvant nivolumab and nab-paclitaxel before cystectomy for patients with muscle-invasive bladder cancermuscle-invasive bladder cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-005050-20-ITOSPEDALE SAN RAFFAELE29
Not Yet Recruiting
Phase 2
A study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in patients affected by high-risk prostate cancer
2024-514580-26-00Ospedale San Raffaele S.r.l.59
Recruiting
Phase 2
A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancerstomach cancergastric cancer1001799010017991
NL-OMON53113Antoni van Leeuwenhoek Ziekenhuis207
Active, Not Recruiting
Phase 1
A randomised trial for gastric cancer with neo-adjuvant chemotherapy, chemoradiotherapy and surgery
EUCTR2015-004627-31-NLThe Netherlands Cancer Institute
Active, Not Recruiting
Phase 1
A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinomahigh risk, surgically resectable, stage III Cutaneous Squamous Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10041834Term: Squamous cell carcinoma of skinSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2019-001469-34-ITFONDAZIONE MELANOMA ONLUS25